New combo therapy aims to boost immune attack on eye cancer
NCT ID NCT07203391
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 28 times
Summary
This early-stage trial tests whether adding a new drug, roginolisib, to the standard treatment tebentafusp is safe and tolerable for people with advanced uveal melanoma, a rare eye cancer. The study enrolls 8 adults whose cancer has spread and who are already on tebentafusp. The goal is to find the best dose and see if the combination helps the immune system fight the cancer longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA, METASTATIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Alfred Hospital
NOT_YET_RECRUITINGMelbourne, Victoria, Australia
Contact
-
St Vincents Hospital
RECRUITINGSydney, New South Wales, 2010, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.